Abstract Organic nanoparticles of bifenthrin (agricultural insecticide) were successfully synthesized by the laser ablation of solids in liquids (LASL) technique, using as liquid medium a solution of a polymeric surfactant at 0.1 %. The results showed that the use of the surfactant improves the stability of the organic nanoparticles 18 times as compared to those synthesized in water. The characterization by UV-Vis spectroscopy allowed evaluating the stability of colloids, as well as determining the concentration of nanoparticles in the medium. In the characterization by TEM and HRTEM was possible to observe nanoparticles with the most probable size of 5 nm and interplanar distances which correspond to the crystalline structure of the starting material. Mass coupled gas chromatography technique was used to corroborate the chemical composition of nanoparticles. Results of biological tests using Drosophila Melanogaster fly, showed that the use of the nanostructured compound is effective in lower doses than those used in agriculture in the form of bulk material.

The aim of this study was to develop a patient-centered quality management system model to be used at hospitals to improve their pharmacovigilance practices. We demonstrated applicability and feasibility of 66 quality indicators by using the Delphi method, in 2 rounds, by a panel of 14 experts. Using the final set of indicators, diagnostic evaluation of the pharmacovigilance unit was performed at 8 Mexican hospitals ('ASEGUREMHOS' hospital network) in order to validate the quality assessment items. Here we present the first model to manage and measure quality of hospital-based pharmacovigilance systems in Mexico and Latin America. Our work encourages the use of good pharmacovigilance practices to improve patient safety at hospitals.

En este trabajo se demostró la pertinencia y validez de 66 indicadores diseñados para la evaluación y seguimiento de las unidades de farmacovigilancia hospitalaria y seleccionados bajo el marco de un sistema de gestión integral de la calidad centrado en el paciente. Para seleccionar los indicadores con mayor relevancia y viabilidad se empleó el método Delphi en dos rondas de consulta a 14 expertos. Posteriormente se validaron a través de la aplicación del instrumento de indicadores a las unidades de farmacovigilancia hospitalaria de los ocho hospitales que conforman la red ASEGUREMHOS. El modelo de gestión desarrollado pretende contribuir al fortalecimiento de las unidades de farmacovigilancia hospitalaria en México y Latinoamérica a través del cumplimiento de estándares que garantizan las buenas prácticas de farmacovigilancia específicamente en el ámbito hospitalario.

Objective: To evaluate effectiveness of treatment with plerixafor in patients undergoing posterior mobilization for hematopoietic transplant at our hospital. Methods: Retrospective study of all patients who until September 2012, received plerixafor in their scheme of mobilization into peripheral blood hematopoietic progenitors. We reviewed the medical records and records of drug dispensing outpatient consultation. Effectiveness variables used were: CD34/kg in apheresis product obtained, and day dose received colony stimulating factor (G-CSF) and Plerixafor. Each patient was compared to the effectiveness of the drug results with those obtained earlier mobilization schemes where Plerixafor not used, if present. Data were analyzed using IBM SPSS v19. Results: A total of 24 patients received plerixafor in our hospital. Diagnoses were distributed: 15 NHL, 6 patients with multiple myeloma, 2 Hodgkin's disease, and one metastatic choriocarcinoma. The effectiveness outcomes were no plerixafor mobilization (n = 18): 5 patients were mobilized with G-CSGF only, 13 with G-CSF and chemotherapy. The G-CSF dose / day was mcg 931.1 (± 179.5) for 9.5 days (± 4.7). The average product obtained CD34/kg in cells was 0.2 (± 0.5). No patient received sufficient product (> 2 x 10(6) cells/kg) for subsequent autologous transplantation. 100% of the demonstrations failed. Mobilization with plerixafor (n = 24): 13 patients were mobilized with G-CSGF only, 11 with G-CSF and chemotherapy. The G-CSF dose/ day and averaged Plerixafor mcg 885.1 (± 240.1) and 19.8 (± 4.4), respectively, administered for 8.9 (± 5.1) and 1 , 5 (± 0.6) days, respectively. The average product obtained in CD34/kg was 2.3 x 10(6) cells (± 1.7) (p = 0.014 in relation to the demonstrations without Plerixafor). Only 12.5% (n = 3) patients were unable to undergo autologous transplant. Conclusions: In our patients, plerixafor has proven effective in mobilizing hematopoietic progenitors for autologous back.

Objetivo: Evaluar efectividad del tratamiento con plerixafor en pacientes sometidos a movilización para posterior autotrasplante de progenitores hematopoyéticos en nuestro hospital. Métodos: Estudio retrospectivo de todos los pacientes que hasta septiembre 2012, recibieron plerixafor en su esquema de movilización de progenitores hematopoyéticos a sangre periférica. Se revisaron las historias clínicas y los registros de dispensación de medicamentos de la consulta de pacientes externos. Las variables de efectividad utilizadas fueron: CD34/kg en producto de aféresis obtenidas, dosis y días recibidos de factor estimulante de colonias (G-CSF) y de plerixafor. Para cada paciente se comparó los resultados de efectividad del fármaco con los obtenidos para anteriores esquemas de movilización en los que no se utilizó plerixafor, en caso de tenerlos. Los datos se analizaron mediante IBM spss v19. Resultados: Un total de 24 pacientes recibieron plerixafor en nuestro hospital. Los diagnósticos se distribuyeron: 15 linfoma no Hodgkin , 6 pacientes con mieloma múltiple, 2 enfermedad de Hodgkin, y 1 coriocarcinoma diseminado. Los resultados de efectividad fueron: Movilización sin plerixafor (n = 18): 5 pacientes se movilizaron sólo con G-CSGF, 13 con G-CSF y quimioterapia. La dosis de G-CSF /día fue de 931,1 mcg (± 179,5), durante 9,5 días (± 4,7). El promedio de CD34/kg en producto obtenido fue de 0,2 células (± 0,5). Ningún paciente obtuvo producto suficiente (> 2 x 10(6) células/kg) para el posterior autotrasplante. El 100 % de las movilizaciones fracasaron. Movilización con plerixafor (n = 24): 13 pacientes se movilizaron sólo con G-CSGF, 11 con G-CSF y quimioterapia. La dosis de G-CSF /día y de plerixafor promedio fue de 885,1 mcg (± 240,1) y 19,8 (± 4,4), respectivamente, administrados durante 8,9 (± 5,1) y 1,5 (± 0,6) días, respectivamente. El promedio de CD34/kg en producto obtenido fue de 2,3x10(6) células (±1,7) (p = 0,014, en relación a las movilizaciones sin plerixafor). Sólo el 12,5% (n = 3) pacientes no pudieron someterse a autotrasplante. Conclusiones: En nuestros pacientes, plerixafor ha demostrado ser efectivo en la movilización de progenitores hematopoyéticos para posterior autotrasplante.

A cross-sectional descriptive study was carried out to evaluate the therapeutic results of the anti-inflammatory therapy based on mouthwashes with Vimang extract infusion and applied to a female patient who worn an acrylic denture and had her mucosa affected by first degree denture stomatitis. The natural product served to eliminate the lesion because of its great anti-inflammatory capacity; she was advised to use it four times a day and to take her denture out at night before going to sleep. Curing was observed 5 days after Vimang application; the main sign was the feeling of oral mucosa retraction. No adverse effects were noted, so a long-term use of this product was recommended.

Se realizó un estudio descriptivo y transversal con el objetivo de evaluar los resultados terapéuticos de la terapia antiinflamatoria con extracto de Vimang mediante los enjuagatorios de su infusión, en una paciente portadora de prótesis con base acrílica y con mucosa afectada por estomatitis subprotésis grado I. El producto natural se utilizó en la eliminación de dicha lesión por su gran poder antiinflamatorio; fue indicado 4 veces al día con descanso de su prótesis en el horario nocturno antes de dormir. Se observó la curación a los 5 días de aplicado y como principal manifestación la sensación de recogimiento de la mucosa bucal. No se reflejaron reacciones adversas, por lo que recomendamos su uso a largo plazo.

The aim of this work is to study the importance of minority carrier transport in double barrier diodes (DBD). We propose a theoretical model capable to describe the photoluminescence properties observed in GaAs-Al0.35Ga0.65As double barrier diodes with the increase of temperature. In this model, we considered that the minority carries (holes) photocreated at the contact of the structure diffuse, drift and then tunnel to the well. To study the influence of previous transport mechanisms, we solved the continuity equation under the influence of an applied bias and an excitation laser light. The theoretical photocurrent and photoluminescence calculations agree quite well with the experimental observations. Within the approaches of our model, we are able to simulate the minority holes mobility from the photocurrent measurements suggesting the use of the experimental technique as a probe of the carrier mobility.